IS Pharma launches Aquoral in UK

CHESTER-based pharmaceutical specialist IS Pharma has announced that it has launched its Aquoral product in the UK.

The AIM-listed firm said that the launch of the drug – an oral spray to combat xerostomia (dry mouth) suffered as a side effect of chemotherapy and radio therapy treatments, adds another product to its range of supportive oncology treatments.

Others include Aloxi, an anti-sickness treatment also offered to chemotherapy patients, and a treatment for the pain associated with oral mucositis which is a serious side effect of chemotherapy and radiotherapy treatment.

IS Pharma CEO Tim Wright said: “The commercial launch of Aquoral in the UK is a further step in the successful implementation of our strategy of building and maintaining a fast growing and profitable specialist pharmaceutical company through the acquisition and growth of specialist hospital medicines.”